Magnetic resonance as initial screening diagnosis of secondary involvement of central nervous system in NHL diffuse large B cell lymphoma
DOI:
https://doi.org/10.31053/1853.0605.v75.n2.17517Keywords:
magnetic resonace, diffuse large B cell lymphoma, central nervous systemAbstract
Background: Central Nervous System (CNS) relapse in Diffuse Large B-cell Lymphoma occurs mostly 6-8 months after disease onset. This has led to propose that CNS infiltration is an early event in the evolution of the disease. We intend to evaluate the role of magnetic resonance imaging (MR) at diagnosis to detect early SNC compromise. Materials and Methods: Prospective longitudinal cohort’s study in DGCB patients treated at Hospital de Clínicas between 2013 and 2015. Skull MRI was performed in all patients at diagnosis and lumbar puncture was done according to predefined risk factors. Results: 35 patients were analyzed. Median age: 68 years (24-85 years). Stage III-IV: 62%, 57% good prognosis according to RIPI score and 43% poor prognosis. MRI was performed in all patients, with no pathological findings in any of them. Twenty-one patients fullfilled criteria for cerebrospinal fluid study. Twenty-two patients were studied and received intrathecal methotrexate prophylaxis. Meningeal relapse was observed in a single patient who had negative studies at diagnosis and had received complete prophylaxis at the end of the 6 R-CHOP series. Conclusions: Only one of the 35 patients relapsed in the CNS. This patient had a noral MRI and CSF study at diagnosis and had received prophylaxis with intrathecal chemotherapy. This results lead us to believe that the value of MRI to detect early infiltration in asymptomatic patients at diagnosis is low.Downloads
References
Stein H, Warnke R CW. Diffuse large B-cell lymphoma, not otherwise specified. In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 4th edition. 2008. p. 233–7.
Siegal T, Goldschmidt N. CNS prophylaxis in diffuse large B-cell lymphoma: If, when, how and for whom? Blood Rev [Internet]. 2012;26(3):97–106. Available from: http://dx.doi.org/10.1016/j.blre.2011.12.001
Patrij K, Reiiser M, Wätsel L, Pels H, Kowoll A, et al. Isolated central nervous system relapse of systemic lymphoma (SCNSL): clinical features and outcome of a retrospective analysis. Ger Med Sci. 2011;9(Doc11).
Non-Hodgkin’s Lymphoma. NCCN Clinical Practice Guidelines in Oncology. B Cell Lymphomas. Version 1.2017. 2017;
Hollender A, Kvaloy S, Nome O, Skovlund E, Lote K, Holte H. Central nervous system involvement following diagnosis of non-Hodgkin’s lymphoma: A risk model. Ann Oncol. 2002;13(7):1099–107.
Non-Hodgkin’s Lymphoma. NCCN Clinical Practice Guidelines in Oncology. Non Hodgkin’s Lymphomas. Version 1.2013. Elsevier; 2013.
Villa D, Connors JM, Shenkier TN, Gascoyne RD, Sehn LH, Savage KJ. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy. Ann Oncol [Internet]. 2010 May 1;21(5):1046–52. Available from: http://annonc.oxfordjournals.org/cgi/doi/10.1093/annonc/mdp432
Mcmillan A, Ardeshna KM, Cwynarski K, Lyttelton M, Mckay P, Montoto S. Guideline on the prevention of secondary central nervous system lymphoma: British Committee for Standards in Haematology. Br J Haematol. 2013;163(2):168–81.
Tai WM, Chung J, Tang PL, Koo YX, Hou X, et al. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab. Ann Hematol [Internet]. 2011 Jul 13;90(7):809–18. Available from: http://link.springer.com/10.1007/s00277-010-1150-7
Kumar A, Vanderplas A, LaCasce AS, Rodriguez MA, Crosby AL, et al. Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era. Cancer [Internet]. 2012 Jun 1;118(11):2944–51. Available from: http://doi.wiley.com/10.1002/cncr.26588
Boehme V, Schmitz N, Zeynalova S, Loeffler M, Pfreundschuh M. CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood [Internet]. 2009 Apr 23;113(17):3896–902. Available from: http://www.bloodjournal.org/cgi/doi/10.1182/blood-2008-10-182253
Zahid MF, Khan N, Hashmi SK, Kizilbash SH, Barta SK. Central nervous system prophylaxis in diffuse large B-cell lymphoma. Eur J Haematol [Internet]. 2016 Aug;97(2):108–20. Available from: http://doi.wiley.com/10.1111/ejh.12763
Akkas BE, Vural GU. The incidence of secondary central nervous system involvement in patients with non-Hodgkin’s lymphoma as detected by 18F-FDG PET/CT. Nucl Med Commun [Internet]. 2013;34(1):50–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23111376
Downloads
Additional Files
Published
How to Cite
Issue
Section
License
The Faculty of Medical Sciences Journal (RFCM) subscribes to the Open Access policy and does not charge authors fees for publishing, nor does it charge readers fees for accessing published articles (APC).
